• Title of article

    Severe Acute Kidney Injury Secondary to Immunoglobulin Infusion in Life-Threatening Guillain Barre Syndrome

  • Author/Authors

    Orquera, José David Neurointensive Care Unit - Sanatorio Pasteur - Catamarca, Argentina , Pernasetti, María Marta Department of Nephrology - Sanatorio Pasteur - Catamarca, Argentina , Ojeda, Patricia Department of Nephrology - Sanatorio Pasteur - Catamarca, Argentina , Agüero, Griselda Department of Neurology - Sanatorio Pasteur - Catamarca, Argentina , Godoy, Daniel Agustín Neurointensive Care Unit - Sanatorio Pasteur - Catamarca, Argentina

  • Pages
    5
  • From page
    44
  • To page
    48
  • Abstract
    Immunoglobulin infusion (IVIG) is one of the first line therapy in Guillain Barre Syndrome (GBS). Several medical complications are associated with GBS (pneumonia, sepsis, deep vein thrombosis, dysautonomy). Acute kidney injury (AKI) is an uncommon complication during IVIG infusion. Several risk factors were associated with AKI during IVIG. These are an older age, previous renal disease, concomitant use of nephrotoxic agents, diabetes mellitus, hypovolemia, sepsis or using of IVIG that contained in its preparation sucrose or mannitol as stabilizers to avoid precipitation and aggregation. Infusion rate and total dose play a determinant role. The most important pathophysiological mechanism of AKI are the osmotic stress applied to the epithelium of proximal tubules and glomeruli. The osmotic overload is principally generated by IVIG stabilizers (sucrose). In general, AKI is reversible but approximately 30% hemodialysis is necessary. It is essential to respect doses, infusion rates and closely monitoring renal function parameters during IVIG infusion.
  • Keywords
    Acute kidney injury (AKI) , Immunotherapy , Immunoglobulin , Acute Flaccid Paralysis , Guillain Barre Syndrome
  • Journal title
    Bulletin of Emergency and Trauma
  • Serial Year
    2022
  • Record number

    2723500